Main study: Heads-Up, Measure-Up 1, Measure-Up 2 and AD-Up. Main driver of decision: There were both positive and negative effects of upadacitinib for indication 1. A considerable advantage, compared to the ACT, was shown for the endpoints remission and pruritus in both male and female subgroups. There were also positive effects for the outcomes patient-reported symptoms in females, and patient-specific directed symptoms in males. No data was available for the assessment of indication 2; there was no suitable data presented for indication 3, as a transfer of results from adults to adolescents was not possible.